Medpace, a privately held, global, full-service clinical research organization is pleased to announce that it has acquired Medical Consulting Dr. Schlichtiger GmbH, a European CRO with extensive drug development expertise providing customized regulatory and pharmacovigilance services to pharmaceutical, biotechnology, and nutritional companies of all sizes based in Munich, Germany.Medical Consulting will add strategic expertise to Medpace in terms of providing centralized European hubs for regulatory submissions and approvals as well as drug safety management and reporting. Medical Consulting is led by Dr. med. Ursula Schlichtiger, General Manager, a research professional with extensive experience in clinical development, regulatory affairs, and pharmacovigilance. Medical Consulting has been working throughout Europe since 1989.

"I am pleased to have Dr. Schlichtiger join the Medpace team to support our growing presence in the European drug development market as Managing Director and Senior Director of Medical and Regulatory Affairs, Europe." said Dr. August Troendle, President and CEO, Medpace. "Dr. Schlichtiger has built a reputation in Europe as a distinguished professional having founded Medical Consulting in 1989 and building the company into an organization widely recognized for their successful interaction with European governmental agencies."

The integration of Medical Consulting Dr. Schlichtiger GmbH will begin immediately with the intent of
completion by mid 2010. The leaders at Medical Consulting will continue in their roles as our businesses
integrate for the significant benefit of our clients.